James Bowen
James D Bowen, MD

James D Bowen, MD

James D Bowen, MD
Specialty

Multiple Sclerosis, Neurology

Clinical Interests / Special Procedures Performed

Multiple Sclerosis, Multiple Sclerosis Clinics at SNI, Neuroimmunology

  • Accepting Children: Yes
  • Accepting New Patients: Yes
  • Accepting Medicare: Yes
  • Accepting Medicaid/DSHS: Yes
Payment Methods Accepted:

Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, Payment Plan, Sliding Fee Scale

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

Clinical Associate Professor of Neurology, University of Washington National Multiple Sclerosis Society, Health Professionals and Researchers Volunteer Hall of Fame


Dr. Bowen was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012)

Nearly 4,500 physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Dr. Bowen was voted "Top Doctors" in Seattle Magazine (2012). 

A survey was mailed to more than 18,000 physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.

News Release

Philosophy of Care

In caring for people with multiple sclreosis and related disorders, it is important to address every aspect of care, including medical and nonmedical issues, to best partner with patients in achieving their highest level of well-being.

Personal Interests

In addition to spending time with my wife and two daughters, I enjoy playing classical guitar, mountaineering, backcountry skiing and home construction projects.

Medical School

Johns Hopkins

Residency

University of Washington

Board Certifications

American Board of Psychiatry and Neurology

Languages:

English

Professional Associations:

American Academy of Neurology

Awards:

National MS Society Volunteer Health Professional and Researchers Hall of Fame

Additional Information:

Clinical Associate Professor of Neurology, University of Washington National Multiple Sclerosis Society, Health Professionals and Researchers Volunteer Hall of Fame


Dr. Bowen was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012)

Nearly 4,500 physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Dr. Bowen was voted "Top Doctors" in Seattle Magazine (2012). 

A survey was mailed to more than 18,000 physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.

News Release

Dr. Bowen’s research interests span a variety of aspects of MS research but particularly emphasize clinical trials of treatments. He is also involved as a peer and ad hoc reviewer for numerous publications and has authored more than 200 articles, abstracts and publications relating to MS and other neurological diseases.

Blood Pressure Medication and Myelin Repair in Multiple Sclerosis

We have received several inquiries about a recent report of a blood pressure medication that helps with myelin repair. This study was reported in Nature Communications: “Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.”

This article received widespread media coverage because it involved a blood pressure medication that is already on the market.

This study used  ...

Roundtable on neuromyelitis optica (NMO)

The neurologists from the MS Center recently attended the Guthy Jackson Charitable Foundation roundtable on neuromyelitis optica (NMO) in Los Angeles. This organization is devoted to improving the care of patients with NMO and promoting research towards finding a cure.


Neurologists from the MS Center at Swedish, Pavle Repovic, MD, PhD, Peiqing Qian, MD, and James Bowen, MD met with Tony Traboulsee, MD, head of the University of British Columbia Hospital MS and NMO programs

NMO often mimics MS, but has characteristic changes on MRI that allow it to be identified. A blood test is available to help with the diagnosis. It is important to recognize the disease because the treatment differs from MS treatments.

Because it is such a rare disease, there are ...

Preliminary results from study of myelin repair

Results were released recently from a study of a medication that may promote myelin repair. The MS Center at Swedish was one of the research sites for this study. The medication, rHIgM22, is an antibody that encouraged myelin repair in animal models. The way that it helps with myelin repair is not known. This study was a phase I study, which means that it was the first time that this medication was used in humans. Phase I studies are done to determine the safety of a medication, and also to help determine the dose of the medication.

In this study, patients ...

Hematopoietic Stem Cells for Multiple Sclerosis

The MS Center at Swedish Neuroscience Institute played a major role in a research study that recently garnered national attention. This research was published in JAMA Neurology. This research investigated the effect of high dose immunosuppressive followed by hematopoietic stem cell therapy.

This therapy consists of collecting hematopoietic stem cells from patients' blood. Patients then undergo an intense course of immunosuppressive therapy with four medications. This therapy is sufficient to eliminate most of the patient’s bone marrow including white blood cells. The hematopoietic stem cells are then given back to the patient so that their bone marrow may be reconstituted. In multiple sclerosis (MS),  the immune system attacks the brain. The hope is that with this therapy the reconstituted immune system will have less of a tendency to attack the brain and that the disease will stabilize.

This is our second study on this technique in MS. The first study investigated the effect of this treatment on patients with more advanced disease. All but  ...

What type of MS do I have?

Traditionally, MS has been divided into four clinical courses: relapsing/remitting, primary progressive, secondary progressive and progressive relapsing. These four were intended as descriptions of the different courses that MS could take in patients, and were not based on any particular understanding of the biology of the disease, the cause of the disease, or even the prognosis of patients with the different types of MS. Over the years, our understanding of MS has improved, and these descriptions of the disease course no longer meet our needs to describe the disease.

Over the past couple of years, there has been a revision of our classification of MS, resulting in a publication in July 2014. The recommendations of this revision have been  ..

Lemtrada is FDA approved for people with relapsing MS

On November 14, 2014, the U.S. Food and Drug Administration (FDA) approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) who have responded inadequately to two or more MS drugs.  Lemtrada is already approved in over 40 countries around the globe including the EU, Canada and Australia.

The FDA approval of Lemtrada is a significant milestone for people living with relapsing MS.  Lemtrada demonstrated superior efficacy over Rebif on annualized relapse rates in two pivotal randomized Phase III open-label rater-blinded studies in patients with relapsing remitting MS which were the basis for approval.  The clinical development program for Lemtrada involved nearly 1,500 patients including patients at the Swedish MS Center with more than ...

Rare infection occurs in patient on Tecfidera

On Tuesday 10/21/14 Biogen announced that a patient treated with Tecfidera developed a rare infection, progressive multifocal leukoencephalopathy (PML). This patient was from Europe and had been treated with Tecfidera for 54 months. For approximately 3 ½ years, this person’s lymphocyte counts were very low, in the 200-500/mm3 range. After an illness lasting about 4 months this patient died from complications of the infection.
 
PML is an infection caused by the JC virus. About half of the population has the JC virus. Once a person has the JC virus, the immune system quickly brings it under control, but the virus remains hidden in the kidneys after that. From the kidney, the virus can periodically flare up and the immune system quickly brings it under control again. There are many other viruses that have this ability to periodically flare up, for example a virus that remains hidden in the nerves of the face can periodically flare up causing fever blisters, or chicken pox virus remains hidden in the nerves and can periodically flare to cause shingles. The JC virus is fairly easy for the immune system to control, and it generally does not cause medical problems. The one exception is PML.
 
PML occurs when the JC virus flares up in a person whose immune system is not normal. In this setting the virus can spread from the kidney to the brain where it causes widespread damage and usually death. This can happen with a number of immune system diseases, or with prolonged courses of chemotherapy. In recent years PML has occurred with other medications that block the immune system.
 
Tecfidera has been a very successful medication used to treat multiple sclerosis. However, it can cause a decrease in the white blood cells and lymphocytes in the blood. This decrease is usually about 30, which is a level that would not be concerning.  About...
Results 1-7 of 23

Offices

Multiple Sclerosis Center
1600 East Jefferson
A Level
Seattle, WA 98122
Phone: 206-320-2200
Fax: 206-320-2560
Map & Directions

Physicians: Is this your profile? Click here for info

Affiliations

This provider is affiliated with: